California is currently home to 5619 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prospective Multicenter Trial to Determine the Efficacy and Outcome of the UCRI Biomarker Panel and Algorithm to Detect Mucosal Healing in Moderate to Severe Ulcerative Colitis Patients.
NCT04897282
Recruiting
The purpose of this research study is to determine the efficacy and outcome of the UCRI (an in-vitro diagnostics device in the form of a blood test and an algorithm) as a tool to detect mucosal healing (level of inflammation in the colon) in people with moderate-to-severe ulcerative colitis treated with anti-TNFα. Another reason is to explore additional biomarkers in blood, stool or voice to detect disease activity and/or mucosal healing. A tool to detect the level of inflammation in the colon b... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/15/2023
Locations: UC Davis Inflammatory Bowel Disease Center, Sacramento, California
Conditions: Ulcerative Colitis
Register for Updates
A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception
NCT04143659
Recruiting
This is a Phase I multicenter, open-label, dose-ranging, three-dose PK and PD study of injectable LB administered as an IM or SQ injection at 40 mg, and subsequently at 50mg SQ and then 60 mg SQ depending on the preliminary pharmacokinetic and pharmacodynamic results obtained with 40 mg dosing.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
08/11/2023
Locations: University of California, Davis, Davis, California
Conditions: Healthy Women, Female Contraception
Register for Updates
Follow-up After Endovascular Repair of Abdominal Aortic Aneurysm
NCT00488943
Recruiting
To collect and analyze clinical follow-up data which can be used to assess the safety, efficacy, and durability of endovascular AAA repair with Zenith and Chuter-Gianturco stent-grafts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Division of Vascular Surgery, SFVAMC, San Francisco, California
Conditions: Abdominal Aortic Aneurysm
Register for Updates
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
NCT04818034
Recruiting
Cystinuria is an inherited autosomal recessive disorder of the kidney that is the result of an inability to reabsorb cystine from the urine. Supersaturation of cystine in the urine produces crystals that precipitate and form stones in the kidney, which can be a cause of obstruction, infection, and chronic kidney disease. Cystine stones constitute a major health challenge for affected individuals with cystinuria because of the frequent recurrence of painful symptoms and the current absence of eff... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Cystinuria
Register for Updates
Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)
NCT04583644
Recruiting
Despite advances in prenatal diagnosis and postnatal therapies, including ECMO (Extracorporeal Membrane Oxygenation), inhaled nitric oxide therapy, and ventilator strategies that minimize ventilator-induced lung injury, morbidity and mortality rates for babies with severe CDH remain high. The rationale for fetal therapy in severe CDH is to promote adequate lung growth for neonatal survival. Prenatal tracheal occlusion obstructs the normal egress of lung fluid during pulmonary development leading... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/10/2023
Locations: University of California San Francisco Fetal Treatment Center, San Francisco, California
Conditions: Congenital Diaphragmatic Hernia
Register for Updates
Defense and Veterans Center for Integrative Pain Management (DVCIPM) Pain Registry Biobank
NCT04004286
Recruiting
This Pain Registry Biobank is a prospective cohort design study whereby data (PASTOR survey, blood and saliva specimens, clinical data) is collected from participants in a longitudinal fashion with continual enrollment.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/10/2023
Locations: Naval Medical Center San Diego, San Diego, California
Conditions: Pain
Register for Updates
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
NCT03240809
Recruiting
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
08/09/2023
Locations: Bausch Site 003, San Diego, California
Conditions: Psoriasis
Register for Updates
Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
NCT04182659
Recruiting
This study aims to look at the long term efficacy of using repetitive transcranial magnetic stimulation (rTMS) in relieving Gulf War Illness related headaches and pain.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/07/2023
Locations: VA Palo Alto, Palo Alto, California
Conditions: Gulf War Syndrome, Gulf War Illness, Headache, Muscle Pain, Joint Pain
Register for Updates
The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis
NCT03631225
Recruiting
The goal of treating patients diagnosed with rheumatoid arthritis (RA) is to achieve remission or low disease activity and thereby prevent joint damage, loss of physical function, and disability. Optimal management requires regular assessment of disease activity, with treatment changes made as needed for optimal efficacy. Vectra is a blood serum test that looks at 12 biomarkers and produces a score on a scale of 1 to 100. The Vectra score has been shown to be the strongest predictor of risk for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: Bio Solutions Clinical Research, La Mesa, California
Conditions: Rheumatoid Arthritis (RA)
Register for Updates
Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)
NCT04557891
Recruiting
There are few treatment options available for patients once they have failed standard psychopharmacological therapy for generalized anxiety disorder. Existing brain stimulation methods such as rTMS fail to target deep brain structures associated with anxiety disorders; structures such as the amygdala. In this double-blind sham-controlled clinical trial, the investigators propose to establish baseline severity of anxiety in 48 patients, then deliver eight treatments over four sessions of focused... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/04/2023
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Generalized Anxiety Disorder
Register for Updates
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
NCT03547115
Recruiting
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/03/2023
Locations: City of Hope, Duarte, California
Conditions: Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
Register for Updates
Venetoclax and Lintuzumab-Ac225 in AML Patients
NCT03867682
Recruiting
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: University of California, Los Angeles, California
Conditions: Acute Myeloid Leukemia, Relapsed Adult AML
Register for Updates